LBPMedicine(SH:688393) Ge Long Hui A P P·2026-02-27 08:21Core Viewpoint - Anping (688393.SH) reported a significant decline in its 2025 annual performance, with a focus on optimizing its business structure and adjusting channel strategies to enhance market penetration [1] Financial Performance - The company achieved an operating revenue of 347.27 million yuan, a year-on-year decrease of 26.24% [1] - The net profit attributable to the parent company was -44.97 million yuan, reflecting a year-on-year decline of 311.22% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was -65.90 million yuan, showing a year-on-year decrease of 562.30% [1] Business Strategy - The company actively optimized its business structure by focusing on the expansion of its main business revenue and correspondingly reducing the scale of its agency product business [1] - To accelerate market penetration, the company is promoting adjustments in its channel strategy, increasing the proportion of distribution channels [1] - The average selling price of products has decreased year-on-year, which has had a short-term impact on overall gross profit [1]